KNC Laboratories (6568) Fundamentals 2026 — P/E 12.7x, Revenue Analysis | SniperIQ
KNC Laboratories (6568) is a JP-listed Basic Materials company in Chemicals with a market capitalization of ¥9.7B, trading at ¥1254.00 on the JPX. This SniperIQ fundamentals page covers KNC Laboratories's valuation (P/E 12.7x, P/B 0.7x), profitability (net margin 8.4%), revenue (¥9.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is KNC Laboratories's market cap?
KNC Laboratories (6568) has a market capitalization of approximately ¥9.7B, trading at ¥1254.00 on the JPX. Market cap moves with the live share price.
What is KNC Laboratories's P/E ratio?
KNC Laboratories's trailing twelve-month P/E ratio is 12.7x, with a price-to-book (P/B) of 0.7x. Valuation multiples are best compared with Basic Materials sector peers rather than read in isolation.
How profitable is KNC Laboratories?
KNC Laboratories runs a net profit margin of 8.4%, a gross margin of 26.3%, and an operating margin of 11.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does KNC Laboratories generate?
KNC Laboratories reported revenue of ¥9.1B for fiscal year 2025, with net income of ¥766M and earnings per share (EPS) of 99.02. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does KNC Laboratories pay a dividend?
KNC Laboratories offers a trailing dividend yield of about 2.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is KNC Laboratories financially healthy?
KNC Laboratories carries a debt-to-equity ratio of 0.26x and a current ratio of 2.87x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is KNC Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For KNC Laboratories (6568) the key facts are: market cap ¥9.7B, P/E 12.7x, revenue ¥9.1B, 52-week range 1060-1418. Weigh valuation, profitability, growth, and balance-sheet strength against Basic Materials peers and form your own view.
Track KNC Laboratories's full fundamentals live
Get KNC Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.